نتایج جستجو برای: flt3 itd

تعداد نتایج: 4119  

2015
Sarah Bertoli Helena Boutzen Laure David Clément Larrue François Vergez Anne Fernandez-Vidal Lingli Yuan Marie-Anne Hospital Jérôme Tamburini Cécile Demur Eric Delabesse Estelle Saland Jean-Emmanuel Sarry Marie-Odile Galcera Véronique Mansat-De Mas Christine Didier Christine Dozier Christian Récher Stéphane Manenti

We investigated cell cycle regulation in acute myeloid leukemia cells expressing the FLT3-ITD mutated tyrosine kinase receptor, an underexplored field in this disease. Upon FLT3 inhibition, CDC25A mRNA and protein were rapidly down-regulated, while levels of other cell cycle proteins remained unchanged. This regulation was dependent on STAT5, arguing for FLT3-ITD-dependent transcriptional regul...

Journal: :Blood 2012
Hannes Leischner Corinna Albers Rebekka Grundler Elena Razumovskaya Karsten Spiekermann Stefan Bohlander Lars Rönnstrand Katharina Götze Christian Peschel Justus Duyster

Mutations of Fms-like tyrosine kinase 3 (FLT3) are among the most frequently detected molecular abnormalities in AML patients. Internal tandem duplications (ITDs) are found in approximately 25% and point mutations within the second tyrosine kinase domain (TKD) in approximately 7% of AML patients. Patients carrying the FLT3-ITD but not the FLT3-TKD mutation have a significantly worse prognosis. ...

Journal: :Blood 2005
Lara Tickenbrock Joachim Schwäble Markus Wiedehage Björn Steffen Bülent Sargin Chunaram Choudhary Christian Brandts Wolfgang E Berdel Carsten Müller-Tidow Hubert Serve

Activating Flt3 mutations occur in about 30% of patients with acute myeloid leukemia (AML), often as in-frame internal tandem duplication (ITD) at the juxtamembrane domain of the receptor. These mutations transform hematopoietic cell lines and primary mouse bone marrow. Here, we analyzed the interaction between oncogenic Flt3-ITD mutations and the Wingless-type (Wnt) signaling pathway in the my...

Journal: :Acta medica Okayama 2017
Yuka Iwasaki Rituo Nishiuchi Michinori Aoe Takahide Takahashi Hirokazu Watanabe Chiho Tokorotani Kiyoshi Kikkawa Akira Shimada

Acute myeloid leukemia (AML) patients with fms-related tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) often have a poor prognosis, even after hematopoietic stem cell transplantation (HSCT). We report a case of AML with FLT3-ITD identified upon initial diagnosis, who received HSCT at complete remission after 3 consecutive chemotherapies. However, the patient relapsed when the same FL...

Journal: :Blood 2003
Christian M Zwaan Soheil Meshinchi Jerald P Radich Anjo J P Veerman Dieuwke R Huismans Leonhard Munske Martina Podleschny Karel Hählen Rob Pieters Martin Zimmermann Dirk Reinhardt Jochen Harbott Ursula Creutzig Gertjan J L Kaspers Frank Griesinger

FLT3 is a receptor tyrosine kinase involved in the proliferation and differentiation of hematopoietic stem cells. FLT3 internal tandem duplications (FLT3/ITDs) are reported in acute myeloid leukemia (AML) and predict poor clinical outcome. We found FLT3/ITDs in 11.5% of 234 children with de novo AML. FLT3/ITD-positive patients were significantly older and had higher percentages of normal cytoge...

2016
Colleen M. Lau Simone A. Nish Nir Yogev Ari Waisman Steven L. Reiner Boris Reizis

A common genetic alteration in acute myeloid leukemia is the internal tandem duplication (ITD) in FLT3, the receptor for cytokine FLT3 ligand (FLT3L). Constitutively active FLT3-ITD promotes the expansion of transformed progenitors, but also has pleiotropic effects on hematopoiesis. We analyzed the effect of FLT3-ITD on dendritic cells (DCs), which express FLT3 and can be expanded by FLT3L admi...

Journal: :Blood 2013
Eric I Zimmerman David C Turner Jassada Buaboonnam Shuiying Hu Shelley Orwick Michael S Roberts Laura J Janke Abhijit Ramachandran Clinton F Stewart Hiroto Inaba Sharyn D Baker

FLT3 kinase internal tandem duplication (ITD) mutations are common in acute myeloid leukemia (AML) and are associated with poor clinical outcomes. Although initial responses to FLT3 tyrosine kinase inhibitors (TKIs) are observed in FLT3-ITD-positive patients, subsequent relapse often occurs upon acquisition of secondary FLT3 kinase domain (KD) mutations, primarily at residues D835 and F691. Usi...

2015
Alexa S. Green Thiago T. Maciel Marie-Anne Hospital Chae Yin Fetta Mazed Elizabeth C. Townsend Sylvain Pilorge Mireille Lambert Etienne Paubelle Arnaud Jacquel Florence Zylbersztejn Justine Decroocq Laury Poulain Pierre Sujobert Nathalie Jacque Kevin Adam Jason C. C. So Olivier Kosmider Patrick Auberger Olivier Hermine David M. Weinstock Catherine Lacombe Patrick Mayeux Gary J. Vanasse Anskar Y. Leung Ivan C. Moura Didier Bouscary Jerome Tamburini

Fms-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) is frequently detected in acute myeloid leukemia (AML) patients and is associated with a dismal long-term prognosis. FLT3 tyrosine kinase inhibitors provide short-term disease control, but relapse invariably occurs within months. Pim protein kinases are oncogenic FLT3-ITD targets expressed in AML cells. We show that increased Pim...

2014
Hanna Janke Friederike Pastore Daniela Schumacher Tobias Herold Karl-Peter Hopfner Stephanie Schneider Wolfgang E. Berdel Thomas Büchner Bernhard J. Woermann Marion Subklewe Stefan K. Bohlander Wolfgang Hiddemann Karsten Spiekermann Harald Polzer

About 30% of patients with acute myeloid leukemia (AML) harbour mutations of the receptor tyrosine kinase FLT3, mostly internal tandem duplications (ITD) and point mutations of the second tyrosine kinase domain (TKD). It was the aim of this study to comprehensively analyze clinical and functional properties of various FLT3 mutants. In 672 normal karyotype AML patients FLT3-ITD, but not FLT3-TKD...

2016
Aoli Wang Hong Wu Cheng Chen Chen Hu Ziping Qi Wenchao Wang Kailin Yu Xiaochuan Liu Fengming Zou Zheng Zhao Jiaxin Wu Juan Liu Feiyang Liu Li Wang Richard M. Stone Ilene A. Galinksy James D. Griffin Shanchun Zhang Ellen L. Weisberg Jing Liu Qingsong Liu

The FLT3-ITD mutation is one of the most prevalent oncogenic mutations in AML. Several FLT3 kinase inhibitors have shown impressive activity in clinical evaluation, however clinical responses are usually transient and clinical effects are rapidly lost due to drug resistance. One of the resistance mechanisms in the AML refractory patients involves FLT3-ligand induced reactivation of AKT and/or E...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید